JY
ZBIO

Jeff Yass’s Zenas BioPharma ZBIO Stock Holding History

Jeff Yass’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Sell
18,900
-39,200
-67% -$779K ﹤0.01% 10012
2026
Q1 		$1.14M Buy
58,100
+51,000
+718% +$1.14M ﹤0.01% 7553
2025
Q4 		$258K Buy
+7,100
New +$234K ﹤0.01% 10302

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jeff Yass's ZBIO Position: Q2 2026 in Review

Jeff Yass sold out of Zenas BioPharma (ZBIO) in Q2 2026, closing a stake of 85,005 shares — an estimated $1.69M sold.

Jeff Yass first reported a position in ZBIO in Q1 2025 and held it in 4 quarters. The position peaked at $1.66M in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Jeff Yass reported no remaining Zenas BioPharma position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 85,005 Zenas BioPharma shares in Q2 2026, an estimated $1.69M.
  • Jeff Yass first reported a position in Zenas BioPharma in Q1 2025 and held it in 4 quarters.
  • Jeff Yass's Zenas BioPharma position peaked at $1.66M in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.